Poster on Immuno Oncology APO010 sensitivity in Multiple Myeloma presented at European Society of Medical Oncology (ESMO)
Poster # 134P: APO010 sensitivity in relapsed Multiple Myeloma patients is presented in Hall E, today: October 10th 2016 at 13-14 CET at ESMO. Please see the attached Poster. Please see the attached Poster. For the related abstract – please refer to: the ESMO website http://www.esmo.org/ as previously announced.
ESMO is the leading European professional organization for medical oncology. Comprising more than 13,000 oncology professionals from over 130 countries. ESMO is the society of reference for oncology education and information.
“Combining APO010 with Drug Response Prediction (DRP™) analysis will add a precision medicine element to immuno-oncology treatment of Multiple Myeloma. The DRP method will enable us to identify patients with high likelihood of response and thereby facilitate focused future trial design and patient recruitment to achieve clinical success with APO010,” Said Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.
ESMO venue: Bella Center, Center Boulevard 5, 2300 Copenhagen, Denmark.
Poster # 134P:
APO010 sensitivity in relapsed Multiple Myeloma patients
will be presented in Hall E, October 10th 2016 at 13-14 CET.
For further information, please contact
Ulla Hald Buhl, COO and or Peter Buhl Jensen, CEO
Chief IR & Communications Mobile: +45 21 60 89 22
Mobile: +45 2170 1049 firstname.lastname@example.org
This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 10th 2016.
About the Drug Response Predictor - DRP™ screening tool
Oncology Venture uses the MPI multi gene DRP™ to select those patients that by the gene signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA.
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. LiPlaCis is being developed in four phase 2 trials and one phase 3 trial in collaboration with Cadila Pharmaceuticals Ltd.